TY - JOUR
T1 - Evidence on clinical relevance of cardiovascular risk evaluation in the general population using cardio-specific biomarkers
AU - Clerico, Aldo
AU - Zaninotto, Martina
AU - Passino, Claudio
AU - Aspromonte, Nadia
AU - Piepoli, Massimo Francesco
AU - Migliardi, Marco
AU - Perrone, Marco
AU - Fortunato, Antonio
AU - Padoan, Andrea
AU - Testa, Angelo
AU - Dellarole, Franco
AU - Trenti, Tommaso
AU - Bernardini, Sergio
AU - Sciacovelli, Laura
AU - Colivicchi, Furio
AU - Gabrielli, Domenico
AU - Plebani, Mario
N1 - Publisher Copyright:
© 2020 Walter de Gruyter GmbH, Berlin/Boston 2020.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for heart failure (HF) progression with hs-cTn methods.
AB - In recent years, the formulation of some immunoassays with high-sensitivity analytical performance allowed the accurate measurement of cardiac troponin I (cTnI) and T (cTnT) levels in reference subjects. Several studies have demonstrated the association between the risk of major cardiovascular events and cardiac troponin concentrations even for biomarker values within the reference intervals. High-sensitivity cTnI and cTnT methods (hs-cTn) enable to monitor myocardial renewal and remodelling, and to promptly identify patients at highest risk ofheart failure. An early and effective treatment of individuals at higher cardiovascular risk may revert the initial myocardial remodelling and slow down heart failure progression. Specific clinical trials should be carried out to demonstrate the efficacy and efficiency of the general population screening by means of cost-benefit analysis, in order to better identify individuals at higher risk for heart failure (HF) progression with hs-cTn methods.
KW - cardiac natriuretic peptides
KW - cardiac troponins
KW - cardiovascular risk
KW - high-sensitivity immunoassay
KW - quality specification
KW - reference population
UR - http://www.scopus.com/inward/record.url?scp=85089099731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089099731&partnerID=8YFLogxK
U2 - 10.1515/cclm-2020-0310
DO - 10.1515/cclm-2020-0310
M3 - Article
C2 - 32692693
AN - SCOPUS:85089099731
SN - 1434-6621
VL - 59
SP - 79
EP - 90
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 1
ER -